The study aimed to investigate how silencing the protein survivin affects the growth of Hep-2 human laryngeal cancer cells both in the lab (in vitro) and in living organisms (in vivo).
Researchers used a specific siRNA to reduce survivin levels, leading to a significant decrease in cell proliferation and a reduction in tumor size in mice.
The results showed that survivin silencing resulted in decreased tumor growth and increased cancer cell death, indicating its potential as a therapeutic target for laryngeal cancer.